A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
General Business and Products Description International Isotopes Inc. (the “Company”, “we”, “us” and “our”) produces an FDA approved generic sodium iodide I-131 drug product, provides radiochemicals for clinical research and life sciences, manufactures a wide range of nuclear medicine calibration and reference standards, is in development of medical devices for the nuclear medicine industry, and produces a variety of cobalt-60 products for medical, research, and industrial applications. We were formed as a Texas corporation in 1995. Our wholly-owned subsidiaries are International Isotopes Idaho Inc., a Texas corporation; International Isotopes Fluorine Products, Inc., an Idaho corporation; International Isotopes Transportation Services, Inc., an Idaho corporation; RadQual, LLC, a limited liability company (RadQual); RadVent, LLC, a limited liability company; Radnostix, LLC, a limited liability company; and TI Services, LLC, a limited liability company (TI Services).
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 14M | 14M | 12M | 11M | 9.7M | 9.4M |
| Net Income | -231K | 9K | -869K | 303K | -902K | 2.2M |
| EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.01 |
| Free Cash Flow | -428K | -82K | 434K | -1.6M | -367K | 1.1M |
| ROIC | -3.5% | 0.2% | -14.3% | 5.0% | -19.2% | 99.9% |
| Gross Margin | 59.9% | 62.2% | 60.2% | 56.3% | 59.4% | 58.3% |
| Debt/Equity | 0.40 | 0.51 | 0.51 | 0.39 | 0.82 | 3.68 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -108K | 7K | -776K | -1.2M | -681K | -416K |
| Operating Margin | -0.8% | 0.0% | -6.3% | -10.8% | -7.0% | -4.4% |
| ROE | -5.6% | 0.2% | -20.7% | 8.6% | -54.6% | 384.0% |
| Shares Outstanding | 528M | 524M | 520M | 515M | 503M | 220M |
INTERNATIONAL ISOTOPES INC passes 4 of 9 quality checks, suggesting mixed fundamentals.
The company's 5-year average ROIC is 14.3% with a gross margin of 59.3%. At current prices, the estimated annualized return to fair value is -23.7%.
INTERNATIONAL ISOTOPES INC (INIS) has a 5-year average return on invested capital (ROIC) of 14.3%. This indicates solid capital allocation.
INTERNATIONAL ISOTOPES INC (INIS) has a market capitalization of $39M. It is classified as a small-cap stock.
INTERNATIONAL ISOTOPES INC (INIS) does not currently pay a regular dividend.
INTERNATIONAL ISOTOPES INC (INIS) operates in the Industrial Instruments For Measurement, Display, And Control industry, within the Technology sector.
INTERNATIONAL ISOTOPES INC (INIS) reported annual revenue of $14 million in its most recent fiscal year, based on SEC EDGAR filings.
INTERNATIONAL ISOTOPES INC (INIS) has a net profit margin of 0.1%. This is a modest margin.
INTERNATIONAL ISOTOPES INC (INIS) generated $-82 thousand in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
INTERNATIONAL ISOTOPES INC (INIS) has a debt-to-equity ratio of 0.51. This indicates moderate leverage.
INTERNATIONAL ISOTOPES INC (INIS) has a return on equity (ROE) of 0.2%. This indicates moderate shareholder returns.
INTERNATIONAL ISOTOPES INC (INIS) has a 5-year average gross margin of 59.3%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 15 years of financial data for INTERNATIONAL ISOTOPES INC (INIS), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
INTERNATIONAL ISOTOPES INC (INIS) has a book value per share of $0.01, based on its most recent annual SEC filing.